Psoriasis

Approximately 14,280 more US patients with psoriasis were estimated to initiate a biologic in Spring than in other seasons, and over 840 more biologic users switched in Spring than in Winter.

This year’s most-popular content on psoriasis include research regarding disparities and socioeconomic factors that impact psoriasis treatment and an interview on shared decision making.

Diagnoses of psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, or undifferentiated inflammatory arthritis saw a dramatic decline during the early stages of the COVID-19 pandemic.

An immune-mediated relationship between the brain and skin has been hypothesized in previous studies about psoriasis.

A review of available literature, although limited, has pointed to a link between pediatric psoriasis and anxiety and depression. Previous research has made a clear association between psoriasis and mood disorders in adults.

Data on the use of biologics for psoriasis among patients with a history of cancer have remained sparse. However, new findings provide the largest amount of real-world data on the use of the biologic secukinumab in these patients.

A prospective study found that patients and providers saw benefits while using a virtual assistant integrated into a teledermatology program.

A brief report found that a need for prior authorization affected biologic approval wait times for patients with psoriasis, especially those with private insurance.

Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.

Black and Hispanic patients living with chronic inflammatory skin disease (CISD) have more barriers to care compared with White patients with CISD, according to a recent study.

Quality of life and sleep quality were both negatively impacted by pruritus when it occurs with psoriasis, according to a recent study.

Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.

In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.

The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

A decade’s worth of retrospective data from over 1 million patients with end-stage renal disease (ESRD) undergoing dialysis showed that psoriasis may be protective against pneumonia in these patients.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.

The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement.

Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.

According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.

Despite incidence of psoriasis decreasing, older populations in Taiwan have a higher risk of developing psoriasis and psoriatic arthritis, according to a recent study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.

Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.

A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis.

Researchers found no evidence of increased risk for severe COVID-19 among children receiving biologic therapies for their psoriasis.

Patients with psoriatic arthritis (PsA) exhibited a higher prevalence of cardiovascular risk factors and events vs the general population, including atherothrombotic disease.

An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.

A systematic review found that skin clearance, symptom control, and treatment safety were among the highest expected outcomes of treatment for patients with psoriasis.